Davis, California
June 1, 2004
Arcadia to further its program
to dDevelop cost-effective source for health-promoting gamma
linolenic acid
Arcadia Biosciences, Inc.,
an agricultural biotechnology company focused on products that
benefit people and the environment, today announced that it has
entered into a funded agreement with
SemBioSys
Genetics Inc., a
Canadian biotechnology company. Under the agreement, SemBioSys
will transform safflower plants using proprietary genes from
Arcadia to create improved seed oils with high levels of gamma
linolenic acid (GLA).
Arcadia will sell the new value-added oils to existing markets for
nutritional ingredients and supplements.
GLA, an omega-6 fatty acid, is an intermediate in human
metabolism and serves as a precursor for a number of
biologically active molecules vital to the maintenance of
membrane structure and normal cell signaling. Scientific
research suggests that GLA may offer benefits for sufferers of
blood platelet dysfunction (thromboembolic disease),
atherosclerosis, rheumatoid arthritis, diabetic neuropathy, and
in the suppression of tumor growth and metastasis. Current
sources used for GLA production - borage oil and evening
primrose oil - make the product expensive and difficult to
manufacture and have limited its production.
"Clinical studies indicate that certain specialty omega-6 fatty
acids are an effective treatment for several debilitating
diseases and disorders, but production costs and relatively low
concentrations from traditional sources have limited widespread
use," said Eric Rey, president of Arcadia Biosciences. "The
production of specialty omega-6 fatty acids in new plant seed
oils could significantly reduce the cost of the substances and
make their health-promoting benefits available to more people.
We believe that this agreement brings an affordable source of
GLA another step closer to becoming a reality."
Arcadia Biosciences is developing a portfolio of agricultural
products that satisfy market needs and at the same time benefit
the environment or human health. Its current product portfolio
includes technologies that enable plants to grow using
significantly less nitrogen fertilizer; plants that grow in soil
too salty for conventional crops; castor plants that do not
produce the toxin ricin; and oilseed plants that contain high
levels of omega-6 fatty acids.
Based in Davis, Calif., Arcadia Biosciences is an
agricultural biotechnology company focused on the development of
profitable agricultural products that improve the environment
and enhance human health. |